Additional Proxy Soliciting Materials (definitive) (defa14a)
August 11 2020 - 5:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the
Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
|
|
|
☐
|
|
Preliminary Proxy Statement
|
|
|
☐
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
|
☐
|
|
Definitive Proxy Statement
|
|
|
☐
|
|
Definitive Additional Materials
|
|
|
☒
|
|
Soliciting Material under §240.14a-12
|
VARIAN MEDICAL SYSTEMS, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|
|
|
|
|
|
|
☒
|
|
No fee required.
|
|
|
☐
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
|
|
|
|
(1)
|
|
Title of each class of securities to which transaction applies:
|
|
|
(2)
|
|
Aggregate number of securities to which transaction applies:
|
|
|
(3)
|
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11
(set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
(4)
|
|
Proposed maximum aggregate value of transaction:
|
|
|
(5)
|
|
Total fee paid:
|
|
|
☐
|
|
Fee paid previously with preliminary materials.
|
|
|
☐
|
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
|
|
|
|
|
(1)
|
|
Amount Previously Paid:
|
|
|
(2)
|
|
Form, Schedule or Registration Statement No.:
|
|
|
(3)
|
|
Filing Party:
|
|
|
(4)
|
|
Date Filed:
|
Announcement Highlights Since announcing Varians agreement to combine with Siemens Healthineers, the Varian team has spent time
connecting with customers, partners and shareholders. Were excited about the positive feedback weve received and support for this significant milestone in our companys history. Together, well create a global innovation leader
on the path to empower clinicians and patients at every stage in the fight against cancer. A Testament to Our Team Siemens Healthineers recognizes the strength of the Varian brand, our cutting-edge portfolio, the relationships weve cultivated,
and the talent of our own marvelous team. Like Varian, Siemens Healthineers is a purpose-driven organization, with a rich history and tradition of leading-edge innovation and a do the right thing mentality and attitude. Dow
Wilson, Varian President and CEO With our support, Varian will make a leap to the next level in cancer care. With the integration of our imaging capabilities, Varian will be able to offer the broadest product portfolio in cancer diagnosis and
therapy. Varian can tap into our vast data pool of curated images in our AI knowledge pool to make use of these new and even more impactful digital and artificial intelligence offerings, and hence, will more quickly broaden the spectrum of more
individualized and more precise therapy. Bernd Montag, Siemens Healthineers CEO Media and Wall Street1 Deal will create a leader in the area of cancer therapy Through the deal to buy Varian, Healthineers acquires the leader in radiation
therapy The purchase will bring together two partners that have collaborated for more than a decade in areas such as radiotherapy diagnostics for cancer treatments Siemens Healthineers expects the prevalence of cancer to almost double between 2010
and 2030, and sees the combination of its own technology in imaging and robotics with Varians in radiation therapy as a means to address a growing, multi-billion dollar market Healthineers has a longstanding relationship with Varian and sees a
good cultural fit. The two companies have been exploring ways to work closer together for some time. The acquisition brings Healthineers one-step closer to the patient The transaction will create a
market-leading end-to-end cancer care provider, bringing together SHLs expertise in imaging diagnostics with VARs broad equipment, software, and service
portfolio in cancer care 1 Permission to quote neither sought nor granted. Testimonials Customer Your is so valuable support .for I love our Varian centre . VitalBeam Customer, Southern India This partnership between a premiere imaging
company with a leading Radiation and Interventional Oncology company is the logical step to tackle this problem [achieving real-time feedback and visualization of the ablation zone]
I wish you the best of luck during this next
chapter in Varians journey. Interventional Solutions Customer, Wisconsin, U.S. Social Buzz On Air
Additional Information About the Merger and Where to Find It This communication relates to the proposed transaction involving Varian.
This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any
jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In connection with the proposed transaction, Varian will file relevant materials with the U.S. Securities and
Exchange Commission (the SEC), including Varians proxy statement on Schedule 14A (the Proxy Statement). This communication is not a substitute for the Proxy Statement or any other document that Varian may file with the
SEC or send to its stockholders in connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF VARIAN ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT, WHEN
THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the documents (when available) free of charge at the SECs website, www.sec.gov, and
Varians website, www.varian.com. In addition, the documents (when available) may be obtained free of charge by directing a request to Investor Relations by email at investors@varian.com or by calling (650)
424-5631. Participants in the Solicitation Varian and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of Varians common stock in
respect of the proposed transaction. Information about the directors and executive officers of Varian is set forth in the definitive proxy statement for Varians 2020 Annual Meeting of Stockholders, which was filed with the SEC on
December 20, 2019, or its Annual Report on Form 10-K for the year ended September 27, 2019, and in other documents filed by Varian with the SEC. Other information regarding the participants in the
proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement and other relevant materials to be filed with the SEC in respect of the proposed transaction
when they become available. Forward-Looking Statements Except for historical information, this communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning
Varians future orders and the anticipated impact of the COVID-19 pandemic on Varians business; and any statements using the terms could, believe, expect,
promising, outlook, should, well-positioned, will or similar statements are forward-looking statements that involve risks and uncertainties that could cause Varians actual results to
differ materially from those anticipated. Such risks and uncertainties include: (1) the future impact of the COVID-19 pandemic on Varians business, including but not limited to, the impact on its
workforce, operations, supply chain, demand for products and services, and Varians financial results and condition; (2) Varians ability to successfully manage the challenges associated with the
COVID-19 pandemic; (3) Varians ability to achieve expected synergies from acquisitions; (4) risks associated with integrating recent acquisitions; (5) global economic conditions and
changes to trends for cancer treatment regionally; (6) currency exchange rates and tax rates; (7) the impact of the Tax Cuts and Jobs Act; (8) the impact of the Affordable Health Care for America Act (including excise taxes on medical
devices) and any further healthcare reforms (including changes to Medicare and Medicaid), and/or changes in third-party reimbursement levels; (9) recent and potential future tariffs or a global trade war; (10) demand for and delays in
delivery of Varians products; (11) Varians ability to develop, commercialize and deploy new products; (12) Varians ability to meet Food and Drug Administration (FDA) and other regulatory requirements, regulations or
procedures; (13) changes in regulatory environments; (14) risks associated with Varian providing financing for the construction and start-up operations of particle therapy centers, challenges
associated with commercializing Varians Proton Solutions business; (15) challenges to public tender awards and the loss of such awards or other orders; (16) the effect of adverse publicity; (17) Varians reliance on sole or
limited-source suppliers; (18) Varians ability to maintain or increase margins; (19) the impact of competitive products and pricing; (20) the potential loss of key distributors or key personnel; (21) challenges related to
entering into new business lines; (22) the occurrence of any event, change or other circumstances that could give rise to the termination of the agreement; (23) the failure to obtain the approval of Varians stockholders, the failure
to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the transaction, (24) risks related to disruption of managements attention from Varians ongoing
business operations due to the transaction; (25) the effect of the announcement of the transaction on the ability of Varian to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does
business, or on its operating results and business generally; (26) the ability to meet expectations regarding the timing and completion of the transaction; and (27) the other risks listed from time to time in Varians filings with the
SEC. For additional information concerning factors that could cause actual results and events to differ materially from those projected herein, please refer to Varians Annual Report on Form 10-K for the
year ended September 27, 2019 and subsequent Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed with the SEC. Varian assumes no obligation to
update or revise the forward-looking statements in this communication because of new information, future events, or otherwise.
Varian Medical System (NYSE:VAR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Varian Medical System (NYSE:VAR)
Historical Stock Chart
From Sep 2023 to Sep 2024